These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32444984)

  • 1. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    Lopez-Leon S; Geissbühler Y; Sabidó M; Turkson M; Wahlich C; Morris JK
    J Neurol; 2020 Sep; 267(9):2721-2731. PubMed ID: 32444984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.
    Andersen JB; Sellebjerg F; Magyari M
    Eur J Neurol; 2023 Jan; 30(1):162-171. PubMed ID: 36098960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.
    Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP
    BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project.
    Dudman DC; Tauqeer F; Kaur M; Ritchey ME; Li H; Lopez-Leon S
    J Neurol; 2022 Feb; 269(2):742-749. PubMed ID: 33792783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
    Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
    Finkelsztejn A; Brooks JB; Paschoal FM; Fragoso YD
    BJOG; 2011 Jun; 118(7):790-7. PubMed ID: 21401856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of levothyroxine supplementation on pregnancy loss and preterm birth in women with subclinical hypothyroidism and thyroid autoimmunity: a systematic review and meta-analysis.
    Rao M; Zeng Z; Zhou F; Wang H; Liu J; Wang R; Wen Y; Yang Z; Su C; Su Z; Zhao S; Tang L
    Hum Reprod Update; 2019 May; 25(3):344-361. PubMed ID: 30951172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
    Amato MP; Portaccio E
    CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy and Family Planning in Multiple Sclerosis.
    Langer-Gould AM
    Continuum (Minneap Minn); 2019 Jun; 25(3):773-792. PubMed ID: 31162316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Portaccio E; Annovazzi P; Ghezzi A; Zaffaroni M; Moiola L; Martinelli V; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Bellantonio P; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
    Neurology; 2018 Mar; 90(10):e823-e831. PubMed ID: 29438046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of surgical therapies for inflammatory bowel disease on female fertility.
    Lee S; Crowe M; Seow CH; Kotze PG; Kaplan GG; Metcalfe A; Ricciuto A; Benchimol EI; Kuenzig ME
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012711. PubMed ID: 31334846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: A descriptive analysis of real-world data.
    Gitman V; Stavropoulos A; Saenz V; Pasquarelli N; Zecevic D; Devonshire V
    Mult Scler Relat Disord; 2022 Jun; 62():103792. PubMed ID: 35452964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.